LU88258I2 - - Google Patents

Info

Publication number
LU88258I2
LU88258I2 LU88258C LU88258C LU88258I2 LU 88258 I2 LU88258 I2 LU 88258I2 LU 88258 C LU88258 C LU 88258C LU 88258 C LU88258 C LU 88258C LU 88258 I2 LU88258 I2 LU 88258I2
Authority
LU
Luxembourg
Prior art keywords
genes
recombinant dna
dna molecules
polypeptides
hosts
Prior art date
Application number
LU88258C
Other languages
English (en)
Inventor
Kenneth Murray
Heinz Ernst Schaller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27260648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88258(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of LU88258I2 publication Critical patent/LU88258I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/223—Hepatitis related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LU88258C 1978-12-22 1979-12-20 LU88258I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB7849907 1978-12-22
GB7850039 1978-12-27
GB7937910 1979-11-01

Publications (1)

Publication Number Publication Date
LU88258I2 true LU88258I2 (fr) 1994-02-03

Family

ID=27260648

Family Applications (4)

Application Number Title Priority Date Filing Date
LU88257C LU88257I2 (fr) 1978-12-22 1979-12-20
LU88258C LU88258I2 (fr) 1978-12-22 1979-12-20
LU88259C LU88259I2 (fr) 1978-12-22 1979-12-21
LU88256C LU88256I2 (fr) 1978-12-22 1979-12-21

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU88257C LU88257I2 (fr) 1978-12-22 1979-12-20

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU88259C LU88259I2 (fr) 1978-12-22 1979-12-21
LU88256C LU88256I2 (fr) 1978-12-22 1979-12-21

Country Status (25)

Country Link
US (1) US4710463A (fr)
EP (2) EP0013828B2 (fr)
JP (5) JP2530801B2 (fr)
AT (1) ATE26127T1 (fr)
AU (1) AU539535B2 (fr)
BR (1) BR7908410A (fr)
CY (1) CY1422A (fr)
DD (1) DD147855A5 (fr)
DE (3) DE2967697D1 (fr)
DK (2) DK171727B1 (fr)
ES (1) ES8105035A1 (fr)
FI (1) FI86437C (fr)
GR (1) GR73675B (fr)
HK (2) HK26688A (fr)
IE (1) IE53176B1 (fr)
IL (1) IL59007A (fr)
IN (1) IN151589B (fr)
LU (4) LU88257I2 (fr)
MX (1) MX9202875A (fr)
NL (2) NL930012I2 (fr)
NO (2) NO794196L (fr)
NZ (1) NZ192465A (fr)
PT (1) PT70626B (fr)
SG (1) SG60387G (fr)
YU (1) YU44186B (fr)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US6297355B1 (en) * 1978-12-22 2001-10-02 Biogen, Inc. Polypeptides displaying HBV antigenicity or hbv antigen specificity
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
USRE34705E (en) * 1979-08-30 1994-08-23 Institut Pasteur Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby
FR2495636B2 (fr) * 1980-12-09 1989-10-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un fragment d'adn circulaire du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
FI83662C (fi) * 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
US5145782A (en) * 1980-12-08 1992-09-08 The Regents Of The University Of California DNA expression vector suitable for direct expression of a foreign gene
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
EP0062286A1 (fr) * 1981-03-31 1982-10-13 Albert Einstein College Of Medicine Of Yeshiva University Test diagnostique du virus de l'hépatite B
US5332664A (en) * 1981-07-15 1994-07-26 Celltech Limited Human calcitonin precursor polyprotein structural gene
EP0340806B1 (fr) * 1981-08-04 1995-05-31 The Regents Of The University Of California Synthèse d'antigènes viraux humains par des levures
US4769238A (en) 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
GR76274B (fr) * 1981-08-04 1984-08-04 Univ California
ZW18282A1 (en) 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
AU8746582A (en) * 1981-09-02 1983-03-10 Biogen N.V. Hepatitis b virus e type antigen
JPS5890517A (ja) * 1981-11-24 1983-05-30 Japan Found Cancer Ｂ型肝炎ウイルスの表面抗原を合成する新規な組換え体及びその製法
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
US7767449B1 (en) * 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
AU1678783A (en) * 1982-07-20 1984-01-26 Molecular Genetics, Inc. Production of herpes simplex viral proteins
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector
GB8321789D0 (en) * 1983-08-12 1983-09-14 Biogen Nv Vaccines and compositions against hepatitis
FR2560890B1 (fr) * 1984-03-07 1987-10-16 Grp Genie Genetique Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
AU579148B2 (en) * 1984-03-09 1988-11-17 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell and b cell determinants
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US5683688A (en) * 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
EP0401941A3 (fr) * 1984-07-11 1991-04-17 Takeda Chemical Industries, Ltd. Antigène de surface du virus de l'hépatite B, et sa production
US4769239A (en) * 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JPS6170989A (ja) * 1984-09-13 1986-04-11 Takeda Chem Ind Ltd 組み換えｄｎａおよびその用途
JPS6226300A (ja) * 1984-10-10 1987-02-04 セントコ−・インコ−ポレ−テツド Ｈｔｌｖ−３ｄｎａのクロ−ニングおよび発現
GB8431171D0 (en) * 1984-12-11 1985-01-23 Technology Licence Co Ltd Monoclonal antibodies
US5853978A (en) * 1985-12-04 1998-12-29 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and methods of use
JPS61233700A (ja) * 1984-12-24 1986-10-17 ジエネンテク，インコ−ポレイテツド 分子クロ−ンされたエイズ関連ポリペプチド
US6534285B1 (en) 1984-12-24 2003-03-18 Genentech, Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
FI861417A0 (fi) * 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
JPH084507B2 (ja) * 1985-10-03 1996-01-24 武田薬品工業株式会社 新規ｄｎａおよびポリペプチド
JPS62236496A (ja) * 1986-04-07 1987-10-16 Green Cross Corp:The ＨＢｓＡｇの製造方法
CA1310602C (fr) * 1986-06-03 1992-11-24 Hajime Horii Promoteur de la levure et procede pour la preparation de proteines heterologues
ES2061500T5 (es) * 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
JPS63214181A (ja) * 1986-07-23 1988-09-06 ベ−リングベルケ、アクチエンゲゼルシャフト ヒト・パピロ−マ・ウイルス１８型の発現生成物、これらのタンパク質に特異的な抗体およびこれらの抗体または対応するｄｎａを含む診断助剤
US4818688A (en) * 1986-11-21 1989-04-04 E. I. Du Pont De Nemours And Company Assays for antibody to hepatitis B core antigen
NZ219515A (en) 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
CA1340173C (fr) * 1987-03-10 1998-12-08 Chudi Guan Production et purification d'une proteine fusionnee a une proteine de liaison
CA1341074C (fr) 1987-06-22 2000-08-08 Hans A. Thoma Particules d'antigene de surface de l'hepatite virale b utilisees comme nouveau vaccin, preparees par procedes d'adn recombinant, composees de differents epitopes et choisies parmi les pre-s et s-peptides
US4880750A (en) * 1987-07-09 1989-11-14 Miragen, Inc. Individual-specific antibody identification methods
WO1989001514A1 (fr) * 1987-08-10 1989-02-23 The University Of Melbourne Clonage moleculaire du gene 9 appartenant au serotype de rotavirus humain 4 et codant pour la proteine vp7 qui est la plus grande glycoproteine specifique de neutralisation de capside externe, et expression de la proteine vp7 ainsi que framgents dudit gene destines a etre utilises en vaccin
EP0311228A3 (fr) * 1987-10-09 1990-05-02 Repligen Corporation Polypeptides recombinants et leur utilisation, y compris un diagnostic pour le virus du SIDA
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
EP0491077A1 (fr) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques
DE4107612A1 (de) * 1991-03-09 1992-09-10 Behringwerke Ag Rekombinante proteine mit der immunreaktivitaet des hepatitis b virus e antigens (hbeag), verfahren zu ihrer herstellung und ihre verwendung in immunoassays und impfstoffen
US5175272A (en) * 1991-08-01 1992-12-29 Becton Dickinson And Company DNA sequences with increased expression of HBcAg
US5175094A (en) * 1991-08-01 1992-12-29 Becton Dickinson And Company Increased expression of HBcAg
US5173427A (en) * 1991-08-01 1992-12-22 Becton Dickinson And Company Vectors and hosts with increased expression of HBCAG
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US5808032A (en) * 1992-03-30 1998-09-15 Suntory Limited Anti-HBS antibody genes and expression plasmids therefor
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5726011A (en) * 1994-03-31 1998-03-10 Virginia Commonwealth University Method for diagnosing chronic hepatitis B virus infection
PT889120E (pt) * 1994-12-09 2002-09-30 Microscience Ltd Genes de virulencia no grupo vgc2 de salmonella
US5993820A (en) * 1996-11-12 1999-11-30 Michigan State University Chimeric LTB vaccines
US20030100520A1 (en) * 1997-01-21 2003-05-29 Philip Needleman Immunological process and constructs for increasing the hdl cholesterol concentration by dna vaccination
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
TR200002338T2 (tr) 1998-02-12 2002-06-21 Immune Complex Corporation Stratejik olarak yenilenmiş hepatit B çekirdek proteinler.
WO1999053046A2 (fr) * 1998-04-14 1999-10-21 Chiron Corporation Technique sans clonage d'expression d'un gene interessant
US6936425B1 (en) * 1998-09-04 2005-08-30 Microscience Limited Attenuated salmonella SP12 mutants as antigen carriers
CZ20011907A3 (cs) 1998-12-04 2002-01-16 Biogen, Inc. Částice jádra HBV s imunogenními sloľkami navázanými prostřednictvím peptidových ligandů
CN100410268C (zh) * 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 免疫原性的乙型肝炎表面抗原在转基因植物中的表达
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
US6268178B1 (en) 1999-05-25 2001-07-31 Phage Biotechnology Corp. Phage-dependent super-production of biologically active protein and peptides
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
US6583279B1 (en) 2001-01-26 2003-06-24 Becton, Dickinson And Company Sequences and methods for detection of hepatitis B virus
US7202354B2 (en) * 2001-03-30 2007-04-10 Abbott Laboratories Hepatitis B virus surface antigen mutant and methods of detection thereof
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
US8876532B2 (en) 2002-07-31 2014-11-04 Dentsply International Inc. Bone repair putty
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method
BRPI0408779A (pt) * 2003-03-26 2006-04-04 Wyeth Corp uso de composições, composição imunogênica e kit
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
GB0420091D0 (en) * 2004-09-10 2004-10-13 Univ Nottingham Trent Medical implant materials
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
GB0514661D0 (en) * 2005-07-16 2005-08-24 Medical Res Council Methods
JP4352032B2 (ja) 2005-08-23 2009-10-28 シャープ株式会社 携帯通信機器
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
ES2341295T3 (es) 2005-09-05 2010-06-17 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2021791A2 (fr) * 2006-05-31 2009-02-11 Unilever N.V. Procédé de criblage d'un composé changeant la pigmentation de la peau et/ou des cheveux
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
CN103911358B (zh) 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
ES2553270T3 (es) 2007-07-27 2015-12-07 Immatics Biotechnologies Gmbh Nuevo epítopo inmunogénico para inmunoterapia
EP2385065A1 (fr) 2007-11-01 2011-11-09 Perseid Therapeutics LLC Polypeptides immunosuppresseurs et acides nucléiques
WO2009068436A1 (fr) * 2007-11-27 2009-06-04 Unilever Plc Procédés de criblage
CN102851313B (zh) * 2008-01-28 2015-01-28 多贝尔有限公司 一种乙型肝炎疫苗及其制备工艺
RS54374B1 (en) 2008-03-27 2016-04-28 Immatics Biotechnologies Gmbh NEW IMMUNOTHERAPY AGAINST TUMORS OF NERVOUS CELLS AND BRAIN
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
WO2009158240A1 (fr) 2008-06-16 2009-12-30 Emergent Product Development Uk Limited Vaccins vectorisés de salmonella contre chlamydia et procédés d’utilisation
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2513146B1 (fr) 2009-12-18 2017-05-03 Kancera AB Anticorps contre ror1 induisant la mort cellulaire de cellules cll
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201219678D0 (en) 2012-11-01 2012-12-12 Benf Ab Ketone body inhibitors and uses thereof
ES2734374T3 (es) 2013-03-01 2019-12-05 Boehringer Ingelheim Animal Health Usa Inc Cuantificación de composiciones de vacuna
TWI777198B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
IL254129B2 (en) 2015-03-27 2023-10-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20180259A1 (es) 2015-07-06 2018-02-05 Immatics Biotechnologies Gmbh Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA54832A (fr) 2016-03-01 2021-12-01 Immatics Biotechnologies Gmbh Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
MY193474A (en) 2016-03-16 2022-10-15 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
FI3430030T3 (fi) 2016-03-16 2024-01-16 Immatics Biotechnologies Gmbh Transfektoituja t-soluja ja t-solureseptoreita käytettäviksi syöpien immunoterapiassa
CR20180530A (es) 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
TWI796314B (zh) 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
WO2018189148A1 (fr) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
SG11201909153UA (en) 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
US10899819B2 (en) 2017-04-10 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
BR112019028070A2 (pt) 2017-07-07 2020-07-14 Immatics Biotechnologies Gmbh peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres
WO2019007974A1 (fr) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc, le cppc et d'autres cancers
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102996A (en) * 1977-04-20 1978-07-25 Merck & Co., Inc. Method of preparing hepatitis B core antigen
US4241175A (en) * 1978-12-18 1980-12-23 Merck & Co., Inc. Assay for hepatitis B core antibody
FR2444713A1 (fr) * 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
JPH0612193B2 (ja) * 1985-08-23 1994-02-16 日立化成工業株式会社 給 湯 機
DE4326945C2 (de) * 1993-08-11 1996-10-24 Schott Glaswerke Regeleinrichtung für die Gaszufuhr zu einer Gaskocheinrichtung mit unter einer durchgehenden Kochfläche angeordneten Gasstrahlungsbrennern

Also Published As

Publication number Publication date
NZ192465A (en) 1983-09-30
ES487106A0 (es) 1981-05-16
DK84194A (da) 1994-07-12
NL930012I1 (nl) 1993-05-03
JP2530801B2 (ja) 1996-09-04
JP2511962B2 (ja) 1996-07-03
IN151589B (fr) 1983-05-28
EP0013828A1 (fr) 1980-08-06
IL59007A (en) 1983-11-30
JPS6352883A (ja) 1988-03-07
EP0374869A1 (fr) 1990-06-27
DE2967697D1 (de) 1990-08-16
DD147855A5 (de) 1981-04-22
HK26688A (en) 1988-04-22
JP2527438B2 (ja) 1996-08-21
CY1422A (en) 1988-09-02
JPS6356292A (ja) 1988-03-10
JPS55104887A (en) 1980-08-11
AU5417079A (en) 1980-06-26
LU88256I2 (fr) 1994-02-03
NO794196L (no) 1980-06-24
LU88257I2 (fr) 1994-02-03
ATE26127T1 (de) 1987-04-15
NO861548L (no) 1980-06-24
YU312779A (en) 1984-02-29
PT70626A (en) 1980-01-01
DE2967652D1 (en) 1987-04-30
EP0013828B1 (fr) 1987-03-25
DK171727B1 (da) 1997-04-14
EP0013828B2 (fr) 1996-03-20
SG60387G (en) 1988-09-23
DE182442T1 (de) 1988-08-11
YU44186B (en) 1990-04-30
FI86437C (fi) 1992-08-25
FI86437B (fi) 1992-05-15
JP2511961B2 (ja) 1996-07-03
AU539535B2 (en) 1984-10-04
MX9202875A (es) 1992-06-30
DK548079A (da) 1980-06-23
JP2512746B2 (ja) 1996-07-03
LU88259I2 (fr) 1994-02-03
JPS63159397A (ja) 1988-07-02
ES8105035A1 (es) 1981-05-16
HK14991A (en) 1991-03-15
US4710463A (en) 1987-12-01
BR7908410A (pt) 1980-09-09
IL59007A0 (en) 1980-03-31
JPS6366129A (ja) 1988-03-24
GR73675B (fr) 1984-03-29
FI794001A (fi) 1980-06-23
IE53176B1 (en) 1988-08-17
IE792494L (en) 1980-06-22
PT70626B (en) 1983-01-10
NL930012I2 (nl) 1994-08-16
NL930013I1 (nl) 1993-05-03

Similar Documents

Publication Publication Date Title
AU539535B2 (en) Recombinant dna molecules
EP0091527A3 (fr) Séquences d'ADN, molécules d'ADN recombinant et procédé de préparation de polypeptides du genre de sérumalbumine humaine
IE811049L (en) Cloned fmdv antigens
KE3747A (en) Recombinant dna,hosts transformed with it and polypeptides produced by the hosts;processes for their preparation;detection processes using the polypeptides;compositions and means containing the polypeptides;dna sequences
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
DK0714441T3 (da) Rekombinante Cladosporium herbarum allergener
MY102686A (en) Recombinant dna molecules and their method of production.
ATA71388A (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung